Nothing Special   »   [go: up one dir, main page]

SG11202000055PA - Antibodies that modulate a biological activity expressed by a cell - Google Patents

Antibodies that modulate a biological activity expressed by a cell

Info

Publication number
SG11202000055PA
SG11202000055PA SG11202000055PA SG11202000055PA SG11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA
Authority
SG
Singapore
Prior art keywords
utrecht
yalelaan
international
cell
bind
Prior art date
Application number
SG11202000055PA
Inventor
Cecilia Anna Wilhelmina Geuijen
Rinse Klooster
Kruif Cornelis Adriaan De
Paulus Johannes Tacken
Mark Throsby
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202000055PA publication Critical patent/SG11202000055PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau vitivio VIII oviolo OH itio oimIE (43) International Publication Date 10 January 2019 (10.01.2019) W I PO I (10) International Publication Number WO 2019/009728 Al PCT (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) CO7K 16/12 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/NL2018/050451 (22) International Filing Date: Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Filing Language: Publication Language: Priority Data: 17180070.9 06 July 2017 (06.07.2017) EP Applicant: MERUS N.V. [NL/NL]; Yalelaan 62, 3584 CM Utrecht (NL). Inventors: GEUIJEN, Cecilia Ana Wilhelmina; c/o Yale- laan 62, 3584 CM Utrecht (NL). KLOOSTER, Rinse; c/ o Yalelaan 62, 3584 CM Utrecht (NL). DE KRUIF, Cor- nelis Adriaan; c/o Yalelaan 62, 3584 CM Utrecht (NL). TACKEN, Paulus Johannes; c/o Yalelaan 62, 3584 CM Utrecht (NL). THROSBY, Mark; c/o Yalelaan 62, 3584 CM Utrecht (NL). LOGTENBERG, Ton; c/o Yalelaan 62, 3584 CM Utrecht (NL). 06 July 2018 (06.07.2018) English English Agent: JANSEN, C.M.; V.O., Carnegieplein 5, 2517 KJ Den Haag (NL). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (25) (26) (30) (71) (72) (74) (81) (84) 1-1 GC N cr\ O O cr\ O 1-1 O (54) Title: ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL (57) : The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lympho- cyte activation 3 (LAG 3) mediated inhibition in a PD- 1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD- 1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD- 1 and a variable domain that can bind to an extracellular part of LAG3.
SG11202000055PA 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell SG11202000055PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180070 2017-07-06
PCT/NL2018/050451 WO2019009728A1 (en) 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell

Publications (1)

Publication Number Publication Date
SG11202000055PA true SG11202000055PA (en) 2020-02-27

Family

ID=59295099

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000055PA SG11202000055PA (en) 2017-07-06 2018-07-06 Antibodies that modulate a biological activity expressed by a cell

Country Status (15)

Country Link
US (2) US11732043B2 (en)
EP (1) EP3649156A1 (en)
JP (2) JP7542436B2 (en)
KR (1) KR20200037250A (en)
CN (3) CN118027197A (en)
AU (1) AU2018297061B2 (en)
BR (1) BR112020000228A2 (en)
CA (1) CA3068933A1 (en)
EA (1) EA202090005A1 (en)
IL (1) IL271833B2 (en)
NZ (1) NZ760655A (en)
PH (1) PH12020550010A1 (en)
SG (1) SG11202000055PA (en)
TW (1) TW201920275A (en)
WO (1) WO2019009728A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117586403A (en) 2016-10-11 2024-02-23 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
CN110121510B (en) 2017-01-06 2024-06-11 克雷森多生物制剂有限公司 Single domain antibodies to programmed cell death (PD-1)
SG11202003978UA (en) 2017-11-13 2020-05-28 Crescendo Biologics Ltd Molecules that bind to cd137 and psma
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019179422A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/lag-3 antibody molecules
US11952424B2 (en) * 2018-03-30 2024-04-09 Merus N.V. Multivalent antibody
CN113727731B (en) * 2019-04-26 2023-06-02 上海药明生物技术有限公司 Bispecific antibodies targeting PD-1 and LAG-3
AR118898A1 (en) 2019-05-09 2021-11-10 Merus Nv VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND THEIR SEPARATION
WO2021242876A1 (en) * 2020-05-27 2021-12-02 Agilent Technologies, Inc. Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc)
CN112225813B (en) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 Antibodies against tetanus toxin and uses thereof
EP4019633A1 (en) * 2020-12-23 2022-06-29 Technische Universität München Conditional cell connectors
CN117177994A (en) 2021-03-31 2023-12-05 美勒斯公司 Multispecific binding moieties comprising novel PD-1 binding domains
JP2024511871A (en) 2021-03-31 2024-03-15 メルス ナムローゼ フェンノートシャップ Novel multispecific antibody
AU2022248913A1 (en) 2021-03-31 2023-11-02 Incyte Corporation Novel pd-1 binding domains
WO2024072893A1 (en) * 2022-09-28 2024-04-04 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
LT2439273T (en) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
JP2012501670A (en) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド PD-1-specific antibodies and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
SI2838918T1 (en) 2012-04-20 2019-11-29 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
EA201691765A1 (en) * 2014-03-14 2016-12-30 Новартис Аг ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016011069A1 (en) 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
JO3663B1 (en) * 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
CA3006224A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
MD3456346T2 (en) * 2015-07-30 2021-11-30 Macrogenics Inc PD-1 and LAG-3 binding molecules and methods of use thereof
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
US11124569B2 (en) 2015-09-18 2021-09-21 Dana-Farber Cancer Institute, Inc. Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
TWI756187B (en) * 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
HUE055222T2 (en) * 2015-10-23 2021-11-29 Merus Nv Binding molecules that inhibit cancer growth
TWI754621B (en) * 2015-11-18 2022-02-11 美商默沙東藥廠 Pd1 and/or lag3 binders
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
JP2019531284A (en) 2016-09-19 2019-10-31 セルジーン コーポレイション Methods of treating immune disorders using PD-1 binding proteins
IL311603A (en) * 2016-09-23 2024-05-01 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
SG11201907561PA (en) * 2017-02-22 2019-09-27 I Mab Anti-lag-3 antibodies and uses thereof
CN110366546A (en) 2017-03-01 2019-10-22 氟化学有限公司法兰克福 The savings medium of new material and its manufacture to be used as in sensitive energy-storage system within the scope of low, medium and high temperature
DE202017102208U1 (en) 2017-03-03 2018-03-07 Sarah Yanik Composition, in particular for the treatment of hoof and claw diseases in animals, and their production
EP3649155A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
CN111094347B (en) * 2017-07-06 2024-09-20 美勒斯公司 Binding molecules that modulate biological activity expressed by cells
JP7375027B2 (en) * 2019-02-14 2023-11-07 メルス ナムローゼ フェンノートシャップ Production of compositions containing two or more antibodies
AU2021279028A1 (en) 2020-05-27 2022-11-17 Dana-Farber Cancer Institute, Inc. Bispecific molecules for selectively modulating T cells

Also Published As

Publication number Publication date
WO2019009728A1 (en) 2019-01-10
CN117964759A (en) 2024-05-03
KR20200037250A (en) 2020-04-08
CN111094350A (en) 2020-05-01
IL271833A (en) 2020-02-27
US20230406932A1 (en) 2023-12-21
JP7542436B2 (en) 2024-08-30
AU2018297061A1 (en) 2020-01-30
PH12020550010A1 (en) 2020-10-12
CN118027197A (en) 2024-05-14
IL271833B1 (en) 2024-05-01
BR112020000228A2 (en) 2020-07-14
NZ760655A (en) 2024-07-05
CN111094350B (en) 2024-09-03
US20200216540A1 (en) 2020-07-09
AU2018297061B2 (en) 2021-05-06
WO2019009728A8 (en) 2020-01-09
EA202090005A1 (en) 2020-06-18
TW201920275A (en) 2019-06-01
IL271833B2 (en) 2024-09-01
CA3068933A1 (en) 2019-01-10
JP2020525533A (en) 2020-08-27
US11732043B2 (en) 2023-08-22
JP2024086853A (en) 2024-06-28
EP3649156A1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201809669RA (en) Use of glutamate modulating agents with immunotherapies to treat cancer
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201909949XA (en) Targeted immunotolerance
SG11201908088RA (en) Antibodies against pd-l1
SG11201811184UA (en) Lag -3 binding members
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201906961UA (en) Polypeptide variants and uses thereof